PSMA PET Prep Product Gozellix Garners FDA Approval
Indicated for use in cases involving suspected metastasis with PCa or suspected PCa recurrence due to elevated PSA level, Gozellix reportedly has a longer shelf life than other gallium-based PET imaging products.
The Food and Drug Administration (FDA) has approved Gozellix® (TLX007-CDx), a new preparation kit for the PSMA PET agent gallium-68 (68Ga) gozetotide.
After radiolabeling with 68Ga, Gozellix is indicated for PSMA PET imaging of men with suspected metastasis of prostate cancer (PCa), according to Telix Pharmaceuticals, the developer of Gozellix. The company said Gozellix is also approved for PSMA PET imaging in cases of suspected PCa recurrence based on elevated prostate-specific antigen (PSA) level.
For men with suspected metastasis or recurrence of prostate cancer, the FDA has approved the use of Gozellix, a preparation kit for the PSMA PET agent 68Ga gozetotide, which offers a longer shelf life (up to six hours) than other gallium-based PSMA PET products, according to Telix Pharmaceuticals, the developer of Gozellix. (Image courtesy of Adobe Stock.)
Telix Pharmaceuticals noted that key advantages with Gozellix include a longer shelf life (up to six hours) in comparison to other gallium-based PSMA PET products. An extended distribution radius may enable the use of Gozellix in PET scanning for areas not being served by other PSMA imaging providers, according to the company.
(Editor’s note: For additional content on prostate cancer imaging, click here.)
Emphasizing the scalable production capability with Gozellix, Telix Pharmaceuticals suggested the product facilitates flexibility with scheduling and efficiency of PSMA PET scanning, bolstering access to the imaging technology for patients with prostate cancer.
“Securing FDA approval for Gozellix is a major win for prostate cancer patients, who gain enhanced access to state-of-the-art 68Ga PSMA-PET imaging,” noted Kevin Richardson, the chief executive officer for Telix Precision Medicine. “With the launch of Gozellix, our team is excited to be bringing the new generation of prostate cancer scanning to more American men, delivered with the reliability, service and flexibility that customers have come to expect from Telix.”
New bpMRI Study Suggests AI Offers Comparable Results to Radiologists for PCa Detection
April 15th 2025Demonstrating no significant difference with radiologist detection of clinically significant prostate cancer (csPCa), a biparametric MRI-based AI model provided an 88.4 percent sensitivity rate in a recent study.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Expanded FDA Approval Allows Use of Pluvicto Prior to Chemotherapy in Patients with mCRPC
March 28th 2025Recent research demonstrated a 59 percent reduced risk of progression or death with the radioligand therapy Pluvicto in comparison to a change of androgen receptor pathway inhibitor (ARPI) for patients with metastatic castration-resistant prostate cancer (mCRPC).
GE HealthCare Launches PET MPI Agent Flyrcado at ACC Conference
March 28th 2025The positron emission tomography myocardial perfusion imaging (PET MPI) agent, which offers a significantly higher half-life than other cardiac PET agents, was recently granted pass-through payment status by CMS that will go into effect on April 1, 2025.
